Reuters logo
BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test
2017年9月13日 / 凌晨5点45分 / 9 天前

BRIEF-Genomic Health and Biocartis announce agreement to develop a breast cancer test

Sept 13 (Reuters) - BIOCARTIS GROUP NV:

* ‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​

* ‍EXCLUSIVE AGREEMENT TO DEVELOP AN IVD VERSION OF ONCOTYPE DX BREAST RECURRENCE SCORE TEST ON BIOCARTIS’ IDYLLA PLATFORM​

* ‍ONCOTYPE DX BREAST RECURRENCE SCORE TEST PLANNED FOR LAUNCH IN EUROPE BEGINNING WITH FRANCE AND GERMANY IN 2019​

* ‍AS PART OF AGREEMENT, GENOMIC HEALTH WILL MAKE A PAYMENT OF APPROXIMATELY $3.3 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q3 OF 2017​

* ‍GENOMIC HEALTH CONTINUES TO EXPECT TO BE PROFITABLE FOR FULL YEAR 2017, EXCLUDING THESE TRANSACTION COSTS​

* ‍UPON COMMERCIALIZATION, GENOMIC HEALTH WILL MAKE ROYALTY PAYMENTS TO BIOCARTIS BASED ON NET SALES OF IVD TESTS DEVELOPED ON BIOCARTIS’ IDYLLA PLATFORM​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below